Literature DB >> 28453833

Vaccination to Reduce Reactivation of Herpes Simplex Virus Type 2.

Jeffrey I Cohen1.   

Abstract

Entities:  

Keywords:  genital herpes; herpes simplex; vaccine; prophylaxis

Mesh：

Substances：

Year:  2017        PMID： 28453833      PMCID： PMC5853953          DOI： 10.1093/infdis/jix006

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  16 in total

1.  ASP2151 for the treatment of genital herpes: a randomized, double-blind, placebo- and valacyclovir-controlled, dose-finding study.

Authors:  Stephen Tyring; Anna Wald; Neddie Zadeikis; Shobha Dhadda; Kazumasa Takenouchi; Ramona Rorig
Journal:  J Infect Dis       Date:  2012-02-20       Impact factor: 5.226

2.  Summary and recommendations from a National Institute of Allergy and Infectious Diseases (NIAID) workshop on "Next Generation Herpes Simplex Virus Vaccines".

Authors:  David M Knipe; Lawrence Corey; Jeffrey I Cohen; Carolyn D Deal
Journal:  Vaccine       Date:  2014-01-28       Impact factor: 3.641

3.  Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial.

Authors:  Anna Wald; Burkhard Timmler; Amalia Magaret; Terri Warren; Stephen Tyring; Christine Johnston; Kenneth Fife; Stacy Selke; Meei-Li Huang; Hans-Peter Stobernack; Holger Zimmermann; Lawrence Corey; Alexander Birkmann; Helga Ruebsamen-Schaeff
Journal:  JAMA       Date:  2016-12-20       Impact factor: 56.272

4.  HIV-1 vaccines and adaptive trial designs.

Authors:  Lawrence Corey; Gary J Nabel; Carl Dieffenbach; Peter Gilbert; Barton F Haynes; Margaret Johnston; James Kublin; H Clifford Lane; Giuseppe Pantaleo; Louis J Picker; Anthony S Fauci
Journal:  Sci Transl Med       Date:  2011-04-20       Impact factor: 17.956

5.  Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials.

Authors:  Christine Johnston; Misty Saracino; Steve Kuntz; Amalia Magaret; Stacy Selke; Meei-Li Huang; Joshua T Schiffer; David M Koelle; Lawrence Corey; Anna Wald
Journal:  Lancet       Date:  2012-01-04       Impact factor: 79.321

6.  Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.

Authors:  Anthony L Cunningham; Himal Lal; Martina Kovac; Roman Chlibek; Shinn-Jang Hwang; Javier Díez-Domingo; Olivier Godeaux; Myron J Levin; Janet E McElhaney; Joan Puig-Barberà; Carline Vanden Abeele; Timo Vesikari; Daisuke Watanabe; Toufik Zahaf; Anitta Ahonen; Eugene Athan; Jose F Barba-Gomez; Laura Campora; Ferdinandus de Looze; H Jackson Downey; Wayne Ghesquiere; Iris Gorfinkel; Tiina Korhonen; Edward Leung; Shelly A McNeil; Lidia Oostvogels; Lars Rombo; Jan Smetana; Lily Weckx; Wilfred Yeo; Thomas C Heineman
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

7.  Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults.

Authors:  Karen E Mark; Anna Wald; Amalia S Magaret; Stacy Selke; Laura Olin; Meei-Li Huang; Lawrence Corey
Journal:  J Infect Dis       Date:  2008-10-15       Impact factor: 5.226

8.  Once-daily valacyclovir to reduce the risk of transmission of genital herpes.

Authors:  Lawrence Corey; Anna Wald; Raj Patel; Stephen L Sacks; Stephen K Tyring; Terri Warren; John M Douglas; Jorma Paavonen; R Ashley Morrow; Karl R Beutner; Leonid S Stratchounsky; Gregory Mertz; Oliver N Keene; Helen A Watson; Dereck Tait; Mauricio Vargas-Cortes
Journal:  N Engl J Med       Date:  2004-01-01       Impact factor: 91.245

Review 9.  Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding.

Authors:  Christine Johnston; Lawrence Corey
Journal:  Clin Microbiol Rev       Date:  2016-01       Impact factor: 26.132

10.  Therapeutic Vaccine for Genital Herpes Simplex Virus-2 Infection: Findings From a Randomized Trial.

Authors:  David I Bernstein; Anna Wald; Terri Warren; Kenneth Fife; Stephen Tyring; Patricia Lee; Nick Van Wagoner; Amalia Magaret; Jessica B Flechtner; Sybil Tasker; Jason Chan; Amy Morris; Seth Hetherington
Journal:  J Infect Dis       Date:  2017-03-15       Impact factor: 5.226
View more
  5 in total

1.  Herpes Simplex Virus Shedding Rate: Surrogate Outcome for Genital Herpes Recurrence Frequency and Lesion Rates, and Phase 2 Clinical Trials End Point for Evaluating Efficacy of Antivirals.

Authors:  Elfriede Agyemang; Amalia S Magaret; Stacy Selke; Christine Johnston; Larry Corey; Anna Wald
Journal:  J Infect Dis       Date:  2018-10-20       Impact factor: 5.226

2.  A trivalent subunit antigen glycoprotein vaccine as immunotherapy for genital herpes in the guinea pig genital infection model.

Authors:  Sita Awasthi; Lauren M Hook; Carolyn E Shaw; Harvey M Friedman
Journal:  Hum Vaccin Immunother       Date:  2017-05-08       Impact factor: 3.452

3.  Successful application of prime and pull strategy for a therapeutic HSV vaccine.

Authors:  David I Bernstein; Rhonda D Cardin; Fernando J Bravo; Sita Awasthi; Peiwen Lu; Derek A Pullum; David A Dixon; Akiko Iwasaki; Harvey M Friedman
Journal:  NPJ Vaccines       Date:  2019-08-01       Impact factor: 7.344

Review 4.  Alphaherpesvirus Vaccines.

Authors:  Clare Burn Aschner; Betsy C Herold
Journal:  Curr Issues Mol Biol       Date:  2020-09-23       Impact factor: 2.081

5.  Triterpenes and Phenolic Compounds from Euphorbia deightonii with Antiviral Activity against Herpes Simplex Virus Type-2.

Authors:  Muhammad Bello Saidu; Norbert Kúsz; Yu-Chi Tsai; Máté Vágvölgyi; Róbert Berkecz; Dávid Kókai; Katalin Burián; Judit Hohmann; Dóra Rédei
Journal:  Plants (Basel)       Date:  2022-03-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.